@arcinstitute: Congrats to @BrianHie, @SynBioGaoLab, and team on Germinal, now out in @NatureBiotech. Their pipeline designs epitope-t…
Summary
Arc Institute announces Germinal, a generative AI system for de novo antibody design published in Nature Biotechnology. It designs epitope-targeted antibodies with nanomolar affinity testing only tens of designs per target, making custom antibody design more accessible.
View Cached Full Text
Cached at: 06/25/26, 05:20 AM
Congrats to @BrianHie, @SynBioGaoLab, and team on Germinal, now out in @NatureBiotech. Their pipeline designs epitope-targeted antibodies with nanomolar affinity while testing only tens of designs per target, making antibody design far more accessible. https://nature.com/articles/s41587-026-03187-0…
Client Challenge
Source: https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41587-026-03187-0&code=3614aef5-363c-43de-b3dc-c4cd7c23e874 A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Arc Institute (@arcinstitute): In another preprint from the @brianhie Lab and @SynBioGaoLab, they introduce Germinal, a generative AI system for de novo antibody design.
Germinal produces functional nanobodies in just dozens of tests, making custom antibody design more accessible than ever before.
Similar Articles
@arcinstitute: One of our most popular preprints of 2025 is now published in @ScienceMagazine. Congrats to @BrianHie, @samuelhking, an…
Arc Institute announces that their popular 2025 preprint on a framework for generating and evaluating AI-generated genomes is now published in Science. The work, from Brian Hie's lab, used Evo 1 and Evo 2 to design viable bacteriophage genomes.
AgForce Enables Antigen-conditioned Generative Antibody Design
This paper identifies three failure modes in existing antibody design methods (antigen blindness, vocabulary collapse, convergence to marginal distribution) and proposes AgForce, a novel encoder-decoder architecture using graph neural networks and mixture density networks, achieving state-of-the-art binding quality and sequence recovery on the Chimera-Bench benchmark.
@SurgeBiswas: New paper from the @nablabio team expanding generative drug design to multispecifics, the intracellular proteome, and p…
Nabla Bio's new paper (JAM-2) expands generative drug design to multispecifics and the intracellular proteome, achieving zero-shot design of a KRAS G12V-targeting bispecific that recruits T cells for picomolar cell killing.
@arcinstitute: The future of biology is agentic. We're proud to work with NVIDIA on the Evo series of models and are excited to see th…
NVIDIA launches the BioNeMo Agent Toolkit, an open toolkit that enables AI agents to perform tasks like protein structure prediction, molecular docking, and generative chemistry, accelerating programmable biology in collaboration with Arc Institute.
@nablabio: Today, we expand zero-shot drug design beyond binding to the design of multifunctional medicines, the intracellular pro…
Nabla Bio unveils JAM-2, a model for zero-shot drug design achieving atomic-precision, computationally designed multispecific antibodies and dual-variant KRAS multispecifics with high potency and selectivity, validated with Cryo-EM and wet-lab experiments.